Business Context and Reporting Period
This Form 8-K reports on the results of the 2021 Annual Meeting of Stockholders held by GlycoMimetics, Inc. on May 18, 2021. The filing details the voting outcomes for three proposals submitted to security holders. Note: The request metadata references "Crescent Biopharma, Inc.", but the filing text explicitly identifies the registrant as GlycoMimetics, Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes and Voting Results
Of the 51,539,010 shares outstanding, 41,319,624 shares (80.17%) were present or represented by proxy. The results for the three proposals were as follows:
- Proposal 1 (Election of Directors): Two nominees, Daniel M. Junius and Rachel K. King, were elected to serve until the 2024 annual meeting.
- Daniel M. Junius: 27,723,181 votes For; 5,098,241 votes Withheld.
- Rachel K. King: 28,163,333 votes For; 4,658,089 votes Withheld.
- Broker Non-Votes: 8,498,202.
- Proposal 2 (Ratification of Auditors): The appointment of Ernst & Young LLP as independent registered public accounting firm was ratified.
- Votes For: 41,160,099
- Votes Against: 107,600
- Abstained: 51,925
- Proposal 3 (Executive Compensation): The advisory vote to approve executive compensation was approved.
- Votes For: 31,828,920
- Votes Against: 380,710
- Abstained: 611,792
- Broker Non-Votes: 8,498,202.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of voting results pursuant to Item 5.07.
Key Facts for Investor Verification
- Verify the registrant name is GlycoMimetics, Inc. (GLYC), not Crescent Biopharma, Inc.
- Confirm the high level of shareholder participation (80.17% of outstanding shares represented).
- Note the significant number of broker non-votes (8,498,202) on the director election and executive compensation proposals.
- Review the definitive proxy statement filed on April 5, 2021, for detailed background on the nominees and compensation plans.